Curated News
By: NewsRamp Editorial Staff
September 10, 2026
Onco-Innovations CMO Highlights ONC010 PNKP Inhibitor in Podcast
TLDR
- Onco-Innovations' ONC010 offers investors a first-mover advantage in PNKP inhibition with dual selectivity for aggressive cancers.
- ONC010 works by inhibiting PNKP to induce synthetic lethality in PTEN or SHP-1 deficient cancer cells and uses nanoparticle delivery.
- Onco-Innovations' ONC010 aims to improve cancer treatment by targeting tumor cells precisely and sparing healthy tissue.
- Onco-Innovations' ONC010 is a novel nanoparticle drug that showed single-agent antitumor activity and prolonged survival in preclinical studies.
Impact - Why it Matters
This news matters because it shines a light on a novel approach to cancer treatment that could overcome limitations of existing therapies. By targeting PNKP, a key enzyme in DNA repair, ONC010 aims to selectively kill cancer cells while sparing healthy tissue—a long-sought goal in oncology. The preclinical success of the nano-formulated inhibitor, including antitumor activity and improved survival in animal models, offers hope for patients with cancers that have limited treatment options. If ONC010 proves safe and effective in human trials, it could represent a significant breakthrough in precision oncology, particularly for tumors with PTEN or SHP-1 deficiencies. Moreover, the collaboration between Onco-Innovations and academic researchers exemplifies the translational research needed to bring innovative therapies from bench to bedside. For investors, this progress signals potential value creation as the company advances toward clinical milestones. Ultimately, the development of ONC010 could contribute to the broader fight against cancer, where new mechanisms of action are urgently needed to address resistance and improve outcomes.
Summary
Onco-Innovations Limited, a Canadian oncology company, is advancing its lead drug candidate ONC010, a novel PNKP inhibitor that targets the DNA repair enzyme polynucleotide kinase phosphatase. In a recent BioMedWire podcast, Chief Medical Officer Dr. Islam Mohamed discussed the company's innovative approach, highlighting ONC010's dual selectivity mechanisms: synthetic lethality designed to limit drug lethality to cancer cells that have lost PTEN or SHP-1, and nanoparticle delivery intended to concentrate the drug within tumor tissue. Preclinical research at the University of Alberta demonstrated that the nano-formulated PNKP inhibitor showed single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. Onco-Innovations holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, positioning it at the forefront of DNA damage response therapies. The company is preparing for a first-in-human clinical program, a critical step toward translating these promising preclinical findings into potential treatments for cancer patients.
Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is dedicated to cancer research and treatment through pioneering research and innovative solutions. The podcast interview with Dr. Mohamed provides valuable insight into the scientific rationale behind ONC010 and the company's strategic focus. For investors and stakeholders, the latest news and updates relating to ONNVF are available in the company's newsroom. The full press release can be accessed via the link provided. This development underscores Onco-Innovations' commitment to advancing novel cancer therapies and highlights the potential of PNKP inhibition as a new clinical target. As the company moves toward clinical trials, the oncology community and investors alike will be watching closely to see if ONC010 can deliver on its early promise.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations CMO Highlights ONC010 PNKP Inhibitor in Podcast
